Mohammed Haffar, MD
Cardiovascular Disease · Hurricane, WVNPI 1275528515
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,894 of the $9,694 with a category attached, or 81.4%. It is spread thinly across 30 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,772 and has fallen 57.0% since, to $1,192 in 2025.
Across 489 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- E.r. Squibb & Sons, L.L.C.$841
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$696
- Abbott$601
- AstraZeneca$578
- plus $4K from 24 others
What the payments were for
- Travel & lodging$1,71418%
- Food & beverage$7,89481%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $1,875 |
| Takeda Pharmaceuticals U.S.A., Inc. | 88 | $1,049 |
| E.r. Squibb & Sons, L.L.C. | 42 | $841 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 44 | $696 |
| Abbott | 33 | $601 |
| AstraZeneca | 28 | $578 |
| Novartis | 38 | $563 |
| Boehringer Ingelheim | 32 | $544 |
| Kestra Medical Technology Services, Inc. | 25 | $487 |
| Johnson & Johnson | 33 | $477 |
| Amgen | 24 | $425 |
| Merck | 19 | $346 |
| Amarin Pharma, Inc. | 17 | $260 |
| Boston Scientific | 10 | $170 |
| Novo Nordisk | 5 | $117 |
| Biotronik Inc. | 5 | $92 |
| Lundbeck LLC | 5 | $87 |
| Pfizer | 6 | $85 |
| Esperion Therapeutics, Inc. | 4 | $60 |
| Heartflow, Inc. | 3 | $56 |
| Baxter Healthcare | 1 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Bayer | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,694 in reported general payments places this provider in the 85th percentile of 100 cardiovascular disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 896 | $748,100 |
| XareltoRivaroxaban | 310 | $292,945 |
| EntrestoSacubitril/Valsartan | 213 | $207,068 |
| JardianceEmpagliflozin | 57 | $45,907 |
| FarxigaDapagliflozin Propanediol | 35 | $19,839 |
| MultaqDronedarone Hcl | 12 | $16,519 |
| Repatha SureclickEvolocumab | 17 | $14,492 |
| Metoprolol Succinate | 1,446 | $13,908 |
| Ranolazine ErRanolazine | 164 | $11,634 |
| VascepaIcosapent Ethyl | 24 | $11,113 |
| Amiodarone Hcl | 493 | $8,254 |
| Propafenone Hcl ErPropafenone Hcl | 54 | $7,426 |
| Propafenone Hcl | 74 | $5,084 |
| NexletolBempedoic Acid | 11 | $4,412 |
| Atorvastatin Calcium | 436 | $2,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $748,100896 claims |
| Johnson & JohnsonXarelto | $477 | $292,945310 claims |
| NovartisEntresto | $563 | $207,068213 claims |
| Boehringer IngelheimJardiance | $544 | $45,90757 claims |
| AstraZenecaFarxiga | $578 | $19,83935 claims |
| Sanofi-aventis U.S. LLCMultaq | $19 | $16,51912 claims |
| Esperion Therapeutics, Inc.Nexletol | $60 | $4,41211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 100 cardiovascular disease providers in West Virginia.
Other cardiovascular disease in Hurricane
- Sarah RinehartCharleston$303K
- Maninder BediWeirton$230K
- Partho SenguptaMorgantown$131K
- Kofi OseiHuntington$87K
- Esam BaryunHuntington$55K
- Mohammad YousafSouth Charleston$34K
- Madhavi KadiyalaMorgantown$29K
- Rameez SayyedHuntington$21K
- David CampseyMorgantown$21K
- Casey HagerSouth Charleston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.